治疗射血分数降低的心力衰竭的药物研究进展

Study progress in pharmacotherapy against heart failure with reduced ejection fraction

心血管疾病是导致死亡的主要原因,并在世界范围内增加卫生保健的费用支出。心力衰竭可简单地描述为心脏无法满足机体的需求,它是很多其他心血管疾病的终点。过去的30年间我们见证了为改善心衰患者存活率及生活质量所做出的巨大努力,其中多数尝试是成功的。考虑到大多数成功的案例都是针对左心室射血分数降低的心力衰竭(reduced left ventricular ejection fraction,HFr EF)患者,本文将针对HFr EF的药物治疗研究进展进行综述,重点介绍临床应用中的新型药物和正处于临床试验中的新型药物。

Cardiovascular diseases represent leading causes of mortality and increased healthcare cost worldwide. Heart failure,which simply describes an inability of the heart to meet the body＇s needs,is the end point for many other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery of treatments to improve the survival and quality of life of patients with heart failure,many of which are successful. Given that most of the successes in treating heart failure are achieved in patients with reduced left ventricular ejection fraction（ HFr EF）,we have conducted this review to look at the recent progress of HFr EF pharmacotherapy,mainly introduce novel pharmacotherapeutic agents in practice and some new drugs under ongoing clinical trials.